The safety and tolerability of pregabalin for the treatment of fibromyalgia-associated pain does not differ by baseline pain severity, a pooled analysis of five phase 3 clinical trials presented at the 2015 ACR/ARHP Annual Meeting has shown.
Phosphodiesterase 5 (PDE5) inhibitors appear to be effective in treating Raynaud’s phenomenon secondary to scleroderma, investigators concluded at the 2015 ACR/ARHP Annual Meeting.
Golimumab was well tolerated and effective in reducing symptom severity and improving disease outcomes in patients with ankylosing spondylitis over 12 months, a Canadian longitudinal study reported at the 2015 ACR/ARHP Annual Meeting.
Transitions from intravenous to subcutaneous administration of abatacept may be associated with diminished disease control in some patients with rheumatoid arthritis (RA), according to a study reported at the 2015 ACR/ARHP Annual Meeting.
Xanthine oxidase inhibitors (XOIs) do not improve uric acid-associated risks for cardiovascular events or deaths among adults, according to a meta-analysis of data pooled from 61 randomized controlled clinical studies, which was reported at the 2015 ACR/ARHP Annual Meeting.
In women with long-standing rheumatic disease there was “no significantly increased risk of malformations or other harmful consequences” in those “exposed to biologic disease-modifying antirheumatic drugs (bDMARDs) before or at conception,” results of a study reported at the 2015 ACR/ARHP Annual Meeting have found.
The selective human anti-interleukin-1β antibody canakinumab demonstrates long-term safety and efficacy for patients with acute gouty arthritis flares, according to a follow-up study reported at the 2015 ACR/ARHP Annual Meeting.
In patients with gout, chronic colchicine use has no effect on the rate of incident coronary artery disease (CAD), a study presented at the 2015 ACR/ARHP Annual Meeting concluded.
Golimumab appears to have similar drug survival at two years in different chronic arthritides regardless of prior biological disease modifying drug (bDMARD) treatment, results of a multicenter prospective observational study reported at the 2015 ACR/ARHP Annual Meeting.
Golimumab ameliorated the significant burden of illness observed in psoriatic arthritis at treatment initiation, reducing symptom severity and improving disease outcomes over 12 months, a study of patients in routine clinical practice in Canada presented at the 2015 ACR/ARHP Annual Meeting has found.
Please login or register first to view this content.
